Physician profile
Aurthur Guerrero
NPI 1346211604
$87,466.98
in general payments reported to CMS, 2019-2025
66 companies · $3,171 in 2025
The $3,171 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $14K · 2021: $4,519 · 2022: $3,338 · 2023: $3,133 · 2024: $3,282 · 2025: $3,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,585.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $50,472.18 | 2019 | |
| Medtronic Minimed, INC. | $8,954.10 | 2019-2020 | |
| Novo Nordisk INC | $8,092.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $3,284.27 | 2019-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $1,383.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,188.07 | 2019-2025 | Tepezza, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,005.37 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals Lp | $960.79 | 2019-2022 | |
| Ibsa Pharma INC. | $921.38 | 2019-2023 | Tirosint, Licart |
| Abbott Laboratories | $895.86 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Medtronic, INC. | $848.04 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Mannkind Corporation | $840.34 | 2019-2025 | Afrezza |
| Insulet Corporation | $835.66 | 2019-2025 | Omnipod, Omnipod |
| Abbvie INC. | $829.97 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $664.45 | 2019-2025 |
Show all 63 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurthur Guerrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.